2637 — Fujian Haixi Pharmaceuticals Co Income Statement
0.000.00%
Last trade - 00:00- HK$10.39bn
- HK$10.46bn
- CNY466.68m
Annual income statement for Fujian Haixi Pharmaceuticals Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS |
| Standards: | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final |
| Revenue | |||
| Total Revenue | 212 | 317 | 467 |
| Cost of Revenue | |||
| Gross Profit | 172 | 264 | 387 |
| Selling / General / Administrative Expenses | |||
| Research And Development | |||
| Unusual Expense / Income | |||
| Total Operating Expenses | 132 | 196 | 341 |
| Operating Profit | 80.4 | 120 | 125 |
| Gain / Loss on Sale of Assets | |||
| Total Net Non Operating Interest Income / Expense | |||
| Other Net Non Operating Costs | |||
| Net Income Before Taxes | 73.8 | 133 | 149 |
| Provision for Income Taxes | |||
| Net Income After Taxes | 69 | 117 | 136 |
| Net Income Before Extraordinary Items | |||
| Net Income | 69 | 117 | 136 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||
| Income Available to Common Shareholders Including Extraordinary Items | |||
| Diluted Net Income | 69 | 117 | 136 |
| Diluted Weighted Average Shares | |||
| Basic EPS Including Extraordinary Items | |||
| Diluted EPS Including Extraordinary Items | |||
| Diluted EPS Excluding Extraordinary Items | |||
| Normalised Income Before Taxes | |||
| Normalised Income After Taxes | |||
| Normalised Income Available to Common Shareholders | |||
| Diluted Normalised EPS | 0.877 | 1.49 | 1.82 |